Cardalis 2.5 mg/20 mg Chewable Tablets for Dogs

In double-blind clinical trials in dogs with congestive heart failure, the veterinary
medicinal product was well tolerated with an incidence of adverse reactions lower
than observed in placebo-treated dogs.
A small number of dogs may exhibit transient vomiting, incoordination or signs of
fatigue.
In rare occasions diarrhoea and anorexia have been reported in dogs.
In cats and dogs with chronic kidney disease, the product may increase plasma
creatinine concentrations at the start of therapy. A moderate increase in plasma
creatinine concentrations following administration of ACE inhibitors is compatible with
the reduction in glomerular hypertension induced by these agents, and is therefore
not necessarily a reason to stop therapy in the absence of other signs.
The veterinary medicinal product may increase food consumption and body weight in
cats.
Emesis, anorexia, dehydration, lethargy and diarrhoea have been reported in rare
occasions in cats.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

Revised: December 2025
MA split from NI Expiry following AN: 02076/2025